Draig Therapeutics Launches with $140 Million (107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric…
Unmatched Grit, Major Glory: J.J. Spaun Conquers Oakmont to Win First Major Championship
HUNTINGTON BEACH, Calif., June 15, 2025 – With unwavering resilience and poise,…
Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems
JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely…
Metamorphoses | 2025 CAA Graduation Season
HANGZHOU, China, June 10, 2025 /PRNewswire/ -- As 2025 approaches its most…
Rakovina Therapeutics Announces the Closing of Oversubscribed Private Placement of $4.9 Million
VANCOUVER, British Columbia, June 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc.…
Sold Out Twice in 6 Months: Pilgrim’s Viral Lipstick Launch Breaks the Internet
MUMBAI, India, June 5, 2025 /PRNewswire/ -- Pilgrim, one of India's fastest-growing…
SafeTree Launches India’s First Maternity Insurance Tailored for IVF Couples with Just 7-Month Waiting Period
NEW DELHI, June 4, 2025 /PRNewswire/ -- In a groundbreaking step towards…
Kia America Posts Eighth Consecutive Month of YearOverYear Sales Growth
79,007 units sold in May, a 5-percent increase compared to previous yearBest-ever…
Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
Phase 2 (Actuate-1801 Part 3B) trial meets primary endpoint and demonstrates a…